Ascentage Pharma to Present Latest Results from Three Preclinical Studies at 2023 American Association for Cancer Research Annual Meeting

SUZHOU, China and ROCKVILLE, Md., March 14, 2023 /PRNewswire/ — Ascentage Pharma (6855.HK), a global biopharmaceutical company developing novel therapies for cancer, chronic hepatitis B (CHB) and age-related diseases, announced today that the latest results from three preclinical studies of the company’s novel third-generation BCR-ABL inhibitor olverembatinib (HQP1351), and two key assets of Ascentage Pharma’s apoptosis-targeting pipeline, the Bcl-2 inhibitor lisaftoclax (APG-2575) and the MDM2 -p53 inhibitor alrizomadline (APG-115). was selected to present at the 2023 American Association of Cancer Research Annual Meeting (AACR 2023). These results provide important insights that will support further advances in the development of innovative therapeutics. Abstracts with these results have already been published on the official AACR website.

The AACR Annual Meeting is one of the world’s largest and oldest scientific gatherings dedicated to cancer research. The annual event covers some of the most innovative advances in all areas of oncology research and innovation and generates tremendous interest from the global cancer research community. This year’s AACR Annual Meeting is taking place 14-19 April 2023In OrlandoFloridaUNITED STATES.

These three abstracts from Ascentage Pharma include:

Olverembatinib (HQP1351)
Olverembatinib (HQP1351) Enhances the Antitumor Effect of Immunotherapy in Renal Cell Carcinoma (RCC)

• Summary number: 5071

• Title: Immunology

• Session title: Combination immunotherapies 1

• session time: Tuesday April 18, 2023, 1:30 p.m. – 5 p.m. EDT

Our results suggest that the combination of olverembatinib with a checkpoint inhibitor (CPI) confers synergistic antitumor effects in an RCC cancer mouse model by targeting tumor growth, angiogenesis, and immune regulation. This novel combination could offer an alternative approach to improve the treatment effects of CPIs in kidney cancer.

Olverembatinib (HQP1351) plus lisaftoclax (APG-2575)
Combination of Olverembatinib (HQP1351) with BCL-2 Inhibitor Lisaftoclax (APG-2575) Overcomes Resistance in Gastrointestinal Stromal Tumors (GISTs)

The story goes on

• Summary number: 1631

• Track: Experimental and Molecular Therapeutics

• Session title: Novel antitumor drugs 3

• session time: Monday 17 April 2023, 9:00 a.m. – 12:30 p.m. EDT

Our results show that olverembatinib and the Bcl-2 inhibitor lisaftoclax have synergistic antitumor effects in imatinib-resistant GIST. Considering that resistance mechanisms are similar for most tyrosine kinase inhibitors (TKIs), this novel dual approach could have potential for treating patients with GIST whose disease has progressed after treatment with imatinib or other TKIs.

Alrizomadline (APG-115)
The MDM2 inhibitor alrizomadlin (APG-115) promotes the antitumor activity of mitogen-activated protein kinase (MAPK) inhibitors in uveal melanoma

• Summary number: 1632

• Track: Experimental and Molecular Therapeutics

• Session title: Novel antitumor drugs 3

• session time: Monday 17 April 2023, 9:00 a.m. – 12:30 p.m. EDT

Our results demonstrate the potential benefit of combining alirizomadlin with inhibitors of the MAPK pathway for the treatment of patients with uveal melanoma.

About Ascentage Pharma

Ascentage Pharma (6855.HK) is a global biopharmaceutical company focused on the development of novel therapies for cancer, chronic hepatitis B and age-related diseases. At October 28, 2019Ascentage Pharma was listed on the Main Board of the Stock Exchange of Hong Kong Limited under share code 6855.HK.

Ascentage Pharma is focused on developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The Company has built a pipeline of 9 clinical drug candidates, including novel, potent Bcl-2 and dual Bcl-2/Bcl-xL inhibitors, as well as candidates targeting IAP and MDM2 p53 pathways and next-generation tyrosine kinase Inhibitors (TKIs). Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of important apoptosis regulators. The company is conducting more than 50 phase I/II clinical trials in the US, Australia, EuropeAnd China. Ascentage Pharma has been nominated for several major national R&D projects, including five major new drug projects, one new drug incubator status, four innovative drug programs, and one major infectious disease prevention and treatment project.

Olverembatinib, the company’s lead drug candidate being developed for the treatment of drug-resistant chronic myeloid leukemia (CML) and the company’s first approved product, has received Priority Review status from the Center for Drug Evaluation (CDE) in China and the National Medicines Agency (NMPA) granted Breakthrough Therapy status. It has also been granted Orphan Drug Designation (ODD) and Fast Track Designation (FTD) by the US FDA and Orphan Designation by the EMA of the EU. To date, Ascentage Pharma has received a total of 16 ODDs from the US FDA and 1 orphan designation from the EU EMA for 4 of the company’s investigational drug candidates.

Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and has formed global partnerships with numerous renowned biotechnology and pharmaceutical companies and research institutes such as UNITY Biotechnology, MD Anderson Cancer Center, Mayo Clinic and Dana-Farber Cancer Institute , MSD and AstraZeneca. The Company has built a talented team with global experience in the discovery and development of innovative medicines and is building its world-class commercial manufacturing and sales and marketing teams. A key goal of Ascentage Pharma is to continually strengthen its R&D capabilities and accelerate its clinical development programs to fulfill its mission of addressing unmet clinical needs China and around the world for the benefit of more patients.

Forward-Looking Statements

The forward-looking statements made in this article speak only as to the events or information as of the date on which the statements in this article are made. Except as required by law, Ascentage Pharma undertakes no obligation to update or publicly revise any forward-looking statements after the date the statements are made, whether as a result of new information, future events or otherwise, or to reflect the event of unforeseen events. You should read this article in its entirety and with the understanding that our actual future results or performance could differ materially from our expectations. This article makes statements or references to our intentions or those of any of our directors or our company as of the date of this article. Any of these intentions may change in light of future developments.

View original content to download multimedia: https://www.prnewswire.com/news-releases/ascentage-pharma-to-present-latest-results-from-three-preclinical-studies-at-2023-american -association-for-cancer-research-annual-meeting-301772332.html

SOURCE Ascentage Pharma